MonoMAC versus idiopathic CD4(+) lymphocytopenia. Comment to Haematologica. 2011;96(8):1221–5

Por Chu, Vicki H., Curry, Jonathan L., Elghetany, M. Tarek, Curry, Choladda V.
Publicado em 2012

Photoallergic reaction in a patient receiving vandetanib for metastatic follicular thyroid carcinoma: a case report

Por Goldstein, Jennifer, Patel, Anisha B., Curry, Jonathan L., Subbiah, Vivek, Piha-Paul, Sarina
Publicado no BMC Dermatol (2015)

Pediatric Subcutaneous Panniculitis-Like T-Cell Lymphoma with Features of Hemophagocytic Syndrome

Por Merritt, Brian Y., Curry, Jonathan L., Duvic, Madeleine, Vega, Francisco, Sheehan, Andrea M., Curry, Choladda V.
Publicado em 2013

Emerging clinical applications of selected biomarkers in melanoma

Por Tetzlaff, Michael T, Torres-Cabala, Carlos A, Pattanaprichakul, Penvadee, Rapini, Ronald P, Prieto, Victor G, Curry, Jonathan L
Publicado no Clin Cosmet Investig Dermatol (2015)

Tissue Resources for Clinical Use and Marker Studies in Melanoma

Por Curry, Jonathan L., Davies, Michael A., Calderone, Tiffany L., Nathanson, Katherine, Prieto, Victor G., Gershenwald, Jeffrey E.
Publicado no Methods Mol Biol (2014)

Dynamic assembly of chromatin complexes during cellular senescence: implications for the growth arrest of human melanocytic nevi

Por Bandyopadhyay, Debdutta, Curry, Jonathan L, Lin, Qiushi, Richards, Hunter W, Chen, Dahu, Hornsby, Peter J, Timchenko, Nikolai A, Medrano, Estela E
Publicado em 2007

H3K79me3T80ph is a Novel Histone Dual Modification and a Mitotic Indicator in Melanoma

Por Martinez, Danielle R., Richards, Hunter W., Lin, Qiushi, Torres-Cabala, Carlos A., Prieto, Victor G., Curry, Jonathan L., Medrano, Estela E.
Publicado em 2012

A case report of Grover’s disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1

Por Uemura, Marc, Faisal, Faa’k, Haymaker, Cara, McQuail, Natalie, Sirmans, Elizabeth, Hudgens, Courtney W., Barbara, Lydia, Bernatchez, Chantale, Curry, Jonathan L., Hwu, Patrick, Tetzlaff, Michael T., Diab, Adi
Publicado no J Immunother Cancer (2016)

Erratum to: A case report of Grover’s disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1

Por Uemura, Marc, Fa’ak, Faisal, Haymaker, Cara, McQuail, Natalie, Sirmans, Elizabeth, Hudgens, Courtney W., Barbara, Lydia, Bernatchez, Chantale, Curry, Jonathan L., Hwu, Patrick, Tetzlaff, Michael T., Diab, Adi
Publicado no J Immunother Cancer (2017)

Impact of the 2009 (7th Edition) AJCC Melanoma Staging System in the Classification of Thin Cutaneous Melanomas

Por Chu, Vicki H., Tetzlaff, Michael T., Torres-Cabala, Carlos A., Prieto, Victor G., Bassett, Roland, Gershenwald, Jeffrey E., McLemore, Michael S., Ivan, Doina, Wang, Wei-Lien (Billy), Ross, Merrick I., Curry, Jonathan L.
Publicado em 2013

NRAS Mutation Status is an Independent Prognostic Factor in Metastatic Melanoma

Por Jakob, John A., Bassett, Roland L., Ng, Chaan S., Curry, Jonathan L., Joseph, Richard W., Alvarado, Gladys C., Rohlfs, Michelle L., Richard, Jessie, Gershenwald, Jeffrey E., Hwu, Patrick, Kim, Kevin B., Lazar, Alexander J., Davies, Michael A.
Publicado em 2011

Sorafenib suppresses JNK-dependent apoptosis through inhibition of ZAK kinase

Por Vin, Harina, Ching, Grace, Ojeda, Sandra S., Adelmann, Charles H., Chitsazzadeh, Vida, Dwyer, David W., Ma, Haiching, Ehrenreiter, Karin, Baccarini, Manuela, Ruggieri, Rosamaria, Curry, Jonathan L., Ciurea, Ana M., Duvic, Madeleine, Busaidy, Naifa L., Tannir, Nizar M., Tsai, Kenneth Y.
Publicado no Mol Cancer Ther (2013)

Utility of BRAF V600E immunohistochemistry expression pattern as a surrogate of BRAF mutation status in 154 patients with advanced melanoma

Por Tetzlaff, Michael T., Pattanaprichakul, Penvadee, Wargo, Jennifer, Fox, Patricia P., Patel, Keyur P., Estrella, Jeannelyn S., Broaddus, Russell R., Williams, Michelle D., Davies, Michael A., Routbort, Mark J., Lazar, Alexander J., Woodman, Scott E., Hwu, Wen-Jen, Gershenwald, Jeffrey E., Prieto, Victor G., Torres-Cabala, Carlos A., Curry, Jonathan L
Publicado no Hum Pathol (2015)

ΔNp63/DGCR8-Dependent microRNAs Mediate Therapeutic Efficacy of HDAC Inhibitors in Cancer

Por Napoli, Marco, Venkatanarayan, Avinashnarayan, Raulji, Payal, Meyers, Brooke A., Norton, William, Mangala, Lingegowda S., Sood, Anil K., Rodriguez-Aguayo, Cristian, Lopez-Berestein, Gabriel, Vin, Harina, Duvic, Madeleine, Tetzlaff, Michael B., Curry, Jonathan L., Rook, Alain H., Abbas, Hussein A., Coarfa, Cristian, Gunaratne, Preethi H., Tsai, Kenneth Y., Flores, Elsa R.
Publicado no Cancer Cell (2016)

BRAF inhibitors suppress apoptosis through off-target inhibition of JNK signaling

Por Vin, Harina, Ojeda, Sandra S, Ching, Grace, Leung, Marco L, Chitsazzadeh, Vida, Dwyer, David W, Adelmann, Charles H, Restrepo, Monica, Richards, Kristen N, Stewart, Larissa R, Du, Lili, Ferguson, Scarlett B, Chakravarti, Deepavali, Ehrenreiter, Karin, Baccarini, Manuela, Ruggieri, Rosamaria, Curry, Jonathan L, Kim, Kevin B, Ciurea, Ana M, Duvic, Madeleine, Prieto, Victor G, Ullrich, Stephen E, Dalby, Kevin N, Flores, Elsa R, Tsai, Kenneth Y
Publicado em 2013

Mutational landscape of aggressive cutaneous squamous cell carcinoma

Por Pickering, Curtis R., Zhou, Jane H., Lee, J. Jack, Drummond, Jennifer A., Peng, S. Andrew, Saade, Rami E., Tsai, Kenneth Y., Curry, Jonathan L., Tetzlaff, Michael T., Lai, Stephen Y, Yu, Jun, Muzny, Donna M., Doddapaneni, Harshavardhan, Shinbrot, Eve, Covington, Kyle R., Zhang, Jianhua, Seth, Sahil, Caulin, Carlos, Clayman, Gary L., El-Naggar, Adel K., Gibbs, Richard A., Weber, Randal S., Myers, Jeffrey N., Wheeler, David A., Frederick, Mitchell J.
Publicado no Clin Cancer Res (2014)